Bethany Lambright Martin

Array ( [id] => 13793369 [patent_doc_number] => 20190010223 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-10 [patent_title] => ANTAGONISTS OF IL-6 TO PREVENT OR TREAT THROMBOSIS [patent_app_type] => utility [patent_app_number] => 15/902041 [patent_app_country] => US [patent_app_date] => 2018-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 87884 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15902041 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12885169 [patent_doc_number] => 20180186898 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-05 [patent_title] => Bispecific Antibodies that Neutralize TNF-alpha and IL-6: Novel Therapeutic Agents for Autoimmune Disease [patent_app_type] => utility [patent_app_number] => 15/897847 [patent_app_country] => US [patent_app_date] => 2018-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18732 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15897847 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13870863 [patent_doc_number] => 20190031772 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-31 [patent_title] => METHODS FOR TREATING AND MONITORING THE STATUS OF CANCER [patent_app_type] => utility [patent_app_number] => 15/894121 [patent_app_country] => US [patent_app_date] => 2018-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18723 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15894121 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12837529 [patent_doc_number] => 20180171016 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-21 [patent_title] => USE OF INTERLEUKIN-4 ANTAGONISTS AND COMPOSITIONS THEREOF [patent_app_type] => utility [patent_app_number] => 15/893101 [patent_app_country] => US [patent_app_date] => 2018-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24138 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15893101 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15178263 [patent_doc_number] => 20190359723 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-28 [patent_title] => ANTIBODY TARGETING IL-13RA2 AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/486481 [patent_app_country] => US [patent_app_date] => 2018-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21420 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16486481 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15099663 [patent_doc_number] => 10471126 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-11-12 [patent_title] => Pegylated interleukin-10 [patent_app_type] => utility [patent_app_number] => 15/889953 [patent_app_country] => US [patent_app_date] => 2018-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7145 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15889953 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13942509 [patent_doc_number] => 10206999 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-02-19 [patent_title] => Antibodies against LIF and uses thereof [patent_app_type] => utility [patent_app_number] => 15/880906 [patent_app_country] => US [patent_app_date] => 2018-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 34 [patent_no_of_words] => 41595 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 147 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15880906 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16770894 [patent_doc_number] => 10981983 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-20 [patent_title] => Antibody targeting interleukin 17A and preparation method and application thereof [patent_app_type] => utility [patent_app_number] => 16/461128 [patent_app_country] => US [patent_app_date] => 2018-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 10102 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16461128 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16805938 [patent_doc_number] => 20210128491 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => USE OF CAROTENOID DERIVATIVES TO REDUCE THE TOXICITY AND INCREASE THE EFFICACY OF ANTI-EGFR ANTITUMOR TREATMENTS [patent_app_type] => utility [patent_app_number] => 16/478915 [patent_app_country] => US [patent_app_date] => 2018-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4097 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16478915 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15664041 [patent_doc_number] => 10596228 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-24 [patent_title] => Methods for increasing levels of interferon activity with an interferon lambda 3 polypeptide [patent_app_type] => utility [patent_app_number] => 15/869503 [patent_app_country] => US [patent_app_date] => 2018-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 62 [patent_no_of_words] => 58136 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15869503 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13300263 [patent_doc_number] => 20180201668 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-19 [patent_title] => In vivo Imaging using Anti-IL-6 Antibodies [patent_app_type] => utility [patent_app_number] => 15/846259 [patent_app_country] => US [patent_app_date] => 2017-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63703 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15846259 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15147823 [patent_doc_number] => 20190352389 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-21 [patent_title] => ANTIBODIES AGAINST LIF AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/470896 [patent_app_country] => US [patent_app_date] => 2017-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41510 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -254 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16470896 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13383745 [patent_doc_number] => 20180243414 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-30 [patent_title] => ANTIBODIES AGAINST LIF AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/845614 [patent_app_country] => US [patent_app_date] => 2017-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41504 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -43 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15845614 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12790804 [patent_doc_number] => 20180155437 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-07 [patent_title] => ANTIBODIES AGAINST HUMAN AND CANINE IL-13RA2 [patent_app_type] => utility [patent_app_number] => 15/835566 [patent_app_country] => US [patent_app_date] => 2017-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12722 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15835566 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14422617 [patent_doc_number] => 10316098 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-06-11 [patent_title] => IL3Ra antibody conjugates and uses thereof [patent_app_type] => utility [patent_app_number] => 15/834211 [patent_app_country] => US [patent_app_date] => 2017-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 34 [patent_no_of_words] => 71457 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15834211 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16406762 [patent_doc_number] => 10815305 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-10-27 [patent_title] => Methods of treating inflammatory conditions [patent_app_type] => utility [patent_app_number] => 15/827357 [patent_app_country] => US [patent_app_date] => 2017-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 39741 [patent_no_of_claims] => 44 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 197 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15827357 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13551885 [patent_doc_number] => 20180327490 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-15 [patent_title] => METHODS FOR TREATING CROHN'S DISEASE USING AN ANTI-IL23 ANTIBODY [patent_app_type] => utility [patent_app_number] => 15/819159 [patent_app_country] => US [patent_app_date] => 2017-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10336 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15819159 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12233188 [patent_doc_number] => 20180066051 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-08 [patent_title] => 'ANTAGONISTS OF IL-17 ISOFORMS AND THEIR USES' [patent_app_type] => utility [patent_app_number] => 15/817934 [patent_app_country] => US [patent_app_date] => 2017-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 13520 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15817934 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12710995 [patent_doc_number] => 20180128831 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-10 [patent_title] => IL-6 SIGNALING AND BREAST CANCER [patent_app_type] => utility [patent_app_number] => 15/806883 [patent_app_country] => US [patent_app_date] => 2017-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17912 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15806883 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15178245 [patent_doc_number] => 20190359714 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-28 [patent_title] => Activatable Anti-CTLA-4 Antibodies and Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/347522 [patent_app_country] => US [patent_app_date] => 2017-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25215 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16347522 [rel_patent_id] =>[rel_patent_doc_number] =>)